- Home
- LCNB vs TLSI Comparison
LCNB vs TLSI Comparison
Compare LCNB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCNB | TLSI |
|---|---|---|
| Founded | 1877 | 2010 |
| Country | United States | United States |
| Employees | N/A | 110 |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.1M | 272.3M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | LCNB | TLSI |
|---|---|---|
| Price | $17.18 | $5.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 19.9K | ★ 141.1K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | $55.47 |
| Revenue Next Year | $3.66 | $40.05 |
| P/E Ratio | $14.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $3.42 |
| 52 Week High | $17.89 | $7.95 |
Technical Indicators
Market Signals| Indicator | LCNB | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 54.27 |
| Support Level | $16.45 | $4.90 |
| Resistance Level | $17.79 | $5.61 |
| Average True Range (ATR) | 0.33 | 0.32 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 14.61 | 87.18 |
Price Performance
Historical ComparisonAbout LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.